SpaceX confirms bond sale as stock declines
SpaceX (NASDAQ:SPCX) has initiated its first-ever bond sale to repay outstanding debt following a 7% decline in its share price during early Monday trade.
SpaceX (NASDAQ:SPCX) has initiated its first-ever bond sale to repay outstanding debt following a 7% decline in its share price during early Monday trade.
Republican Senator Dave McCormick of Pennsylvania joins "Bloomberg Surveillance" to discuss the current state of negotiations with Iran, the death of Alan Greenspan and how the Federal Reserve will operate under its new Chairman Kevin Warsh.
Tarek Robbiati, CFO of data storage company Everpure, said that the increased capex spend on AI is 'not temporary' even if the industry supply and demand equation rebalances and more AI capacity becomes available. Robbiati said that while the AI market is expected to revert to a mean, it will not happen quickly and it may not go back to the same level.
INVO Fertility (NASDAQ:IVF) recorded a 23% increase in year-over-year revenue to $2.02 million for the first quarter of 2026.
NRx Pharmaceuticals (NASDAQ:NRXP) secured FDA authorization for a depression treatment protocol with an initial drug cost of $0.
US Vice President JD Vance says "we laid a very good foundation for a successful final deal." He spoke to reporters in Switzerland after holding talks with Iranian negotiators.
Seema Shah, Principal Asset Management chief global strategist, discusses the near-term inflationary impact of the AI capital expenditure cycle, emphasizing that its implications remain underappreciated by investors. She speaks on "Bloomberg Surveillance."
TScan Therapeutics (NASDAQ:TCRX) reported initial clinical trial data showing 11 out of 14 blood cancer patients achieved complete donor chimerism.
SpaceX is selling investment-grade bonds for the first time to fund the company's AI ambitions following its record IPO. Ed Ludlow has more on "Bloomberg Open Interest."
Eledon Pharmaceuticals (NASDAQ:ELDN) reported extension data showing a 12 mL/min kidney function advantage at 18 months.
Clinical-stage biopharmaceutical firm Traws Pharma (NASDAQ:TRAW) updated guidance for its influenza prophylaxis program to enable a planned Phase 2a trial.
Workforce solutions provider Atlantic International (NASDAQ:ATLN) reported first-quarter 2026 revenue of $249.9 million.